Edition:
India

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

13.24USD
22 Jan 2018
Change (% chg)

$0.20 (+1.53%)
Prev Close
$13.04
Open
$13.03
Day's High
$13.24
Day's Low
$13.03
Volume
87
Avg. Vol
1,360
52-wk High
$17.50
52-wk Low
$10.44

Chart for

About

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a... (more)

Overall

Beta: 1.05
Market Cap(Mil.): £149.65
Shares Outstanding(Mil.): 105.02
Dividend: --
Yield (%): --

Financials

BRIEF-Verona Pharma announces positive top-line data from Phase 2A clinical trial in COPD with RPL554 dosed in addition to Tiotropium

* ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2A CLINICAL TRIAL IN COPD WITH RPL554 DOSED IN ADDITION TO TIOTROPIUM (SPIRIVA) Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

07 Sep 2017

Earnings vs. Estimates